Incidence, timing, refractive patterns, and management of enhancement after keratorefractive lenticule extraction (KLEx): A 3,396-eye single-center registry study
In brief
Revised lenticule-extraction nomogram linked to 73% fewer 12-month enhancements
In a 3,396-eye registry, enhancement occurred in 3.17% of eyes before a revised age-adjusted nomogram and 0.87% afterward when follow-up was equalized. Most enhancements happened within six months, and vision improved after retreatment. The single-center retrospective comparison shows an association, not proof that the nomogram caused the reduction.
- Journal
- Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Q1)
- Published
- 9 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Ivan Gabrić, Mateja Jagić, Karla Bodakoš, Maja Bohač
- PMID
- 43000572
- DOI
- 10.1007/s00417-026-07598-2
Why clinicians should know about it
- Picked for Ophthalmology (paper of the day, 14 November 2026): Large clinical registry reports refractive surgery enhancement outcomes
Abstract
BACKGROUND: The literature on enhancement after keratorefractive lenticule extraction (KLEx) remains limited, particularly when retreatment frequency is anchored to a large real-world denominator. The purpose of this study was to evaluate the incidence, timing, refractive patterns, and management of secondary enhancement after KLEx in a large single-center clinical registry and to examine whether a revised treatment nomogram introduced on July 1, 2024 was associated with lower subsequent enhancement frequency. METHODS: A retrospective registry study was performed at Eye Clinic Svjetlost, Zagreb, Croatia. The denominator registry comprised 3,396 KLEx eyes treated on the SCHWIND ATOS platform. Enhancement eyes were identified from dedicated cap-to-flap and transepithelial photorefractive keratectomy (TransPRK) workbooks. Main outcomes were enhancement rate, time to enhancement, pre-enhancement refractive characteristics, technique distribution, observed postoperative uncorrected distance visual acuity (UDVA), and paired pre-enhancement and postoperative ocular and corneal wavefront measurements. Because postoperative corrected distance visual acuity (CDVA) and postoperative manifest refraction were not systematically captured, directly measured postoperative CDVA was not available and an exploratory surrogate CDVA analysis was performed using pre-enhancement CDVA and observed postoperative UDVA; the safety index derived from this analysis represents an upper-bound estimate and is exploratory only. Exact era denominators were 1,198 eyes before July 1, 2024 and 2,198 eyes on or after July 1, 2024. RESULTS: A total of 61 eyes of 48 patients underwent enhancement, corresponding to an overall enhancement rate of 1.80% (61/3,396; 95% confidence interval [CI], 1.38% to 2.30%). Median time to enhancement was 4.1 months (interquartile range [IQR], 2.7 to 5.5 months; range, 1.1 to 51.0 months), and 47 of 61 eyes (77.0%) were enhanced within 6 months. Kaplan-Meier cumulative incidence with administrative censoring was 0.74% at 3 months, 1.60% at 6 months, 1.92% at 12 months, and 2.26% at 24 months. Mean pre-enhancement spherical equivalent (SEQ) was - 0.80 ± 0.72 D (range, - 2.25 to 1.00 D). Forty eyes underwent cap-to-flap conversion and 21 underwent TransPRK. Cap-to-flap conversion was technically successful in 39 of 40 eyes (97.5%). In harmonized analyses, mean observed UDVA improved from 0.18 ± 0.18 to - 0.03 ± 0.10 logMAR at 1 month (n = 41, P < .001) and from 0.15 ± 0.12 to - 0.05 ± 0.08 logMAR at 3 months (n = 20, P < .001). Ocular wavefront metrics remained stable. Corneal trefoil at 6 mm increased modestly from 0.18 ± 0.09 to 0.22 ± 0.13 μm (n = 58, P = .035) without correlation to latest observed UDVA. Era analysis showed 46 enhancements among 1,198 eyes treated before July 1, 2024 (3.84%) versus 15 among 2,198 eyes treated thereafter (0.68%), corresponding to an 82.2% crude relative reduction (χ² = 43.82, P < .001; risk ratio, 0.18, 95% CI 0.10 to 0.32). After equalizing follow-up time at risk in a landmark analysis, the reduction was more conservative but remained significant (12-month horizon: 3.17% vs. 0.87%; risk ratio 0.27, 95% CI 0.11 to 0.69; P = .003). CONCLUSIONS: Secondary enhancement after KLEx was uncommon in this 3,396-eye registry and usually occurred early after primary surgery. A revised age-adjusted nomogram introduced on July 1, 2024 was associated with a markedly lower enhancement frequency in the subsequent era, an association that persisted after accounting for unequal follow-up time at risk. Cap-to-flap conversion and TransPRK were both feasible enhancement strategies in routine practice, but the principal contribution of this study is denominator-anchored reporting of enhancement incidence, timing, and workflow rather than proof of safety or optical superiority between enhancement techniques.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.